Welcome to CTjobs.com

Work Closer. Work Happier.

Search Jobs

Company hires for CEO jobs in Connecticut

Posted on December 18, 2012

Ikonisys, a provider of cell-based diagnostic solutions, has hired someone for CEO jobs in Connecticut.

James A. Bento has been hired as the company’s newest CEO.

According to an article Bento is charged with taking the company to national prominence, leveraging their leadership in FISH-based laboratory testing in the Northeast.

Ikonisys is known for its patented CellOptics platform and Ikoniscope/Ikonisoft Robotic Microscopy System, which are the keystones to a growing list of proprietary laboratory tests and services that are transforming healthcare throughout the region.

In addition to oncoFISH cervical testing, Ikonisys has developed and is marketing FDA-cleared diagnostic systems that use the Ikoniscope/Ikonisoft system for bladder and breast cancers. This rare cancer cell detection system reduces the subjectivity and fatigue associated with manual test analysis, allowing laboratories to be more productive.

“Without this test, physicians simply do not have a precise enough tool to help assess cervical disease risk for women with abnormal Pap smears,” continued Bento. “Ikonisys is operating Ikonisys Clinical Laboratories (ICL), which are certified by both Clinical Laboratory Improvement Amendments (CLIA) and the College of American Pathologists (CAP). Our laboratory offers the oncoFISH cervical test as a laboratory-developed test. Ikonisys is informing women and their doctors about potential utility of oncoFISH cervical in helping to better manage an abnormal Pap diagnosis and minimize both patient anxiety and possibly unnecessary treatment. The educational process is undertaken by ICL’s own medical sales team, as well as by our partner clinical laboratories. Expanding this educational process is part of my mission with our team.”

“It is very exciting to work with a company whose innovations can truly change the face of healthcare not only in the United States, but also around the world,” said Bento. “Our oncoFISH cervical test is truly an amazing advance in health care for women. When used in conjunction with current practice guidelines for cervical cancer screening, oncoFISH cervical can accurately detect specific genetic changes that can assist the physician in predicting a woman’s probability of progressing to a more serious stage of cervical disease.”

“Our Chief Technology Officer Triantafyllos Tafas and Vice President of Biology Michael Kilpatrick are extraordinary industry leaders and innovators,” said Bento. “Over the past decade, they have developed, tested and patented ground-breaking medical technology. It’s now our job to commercialize these products and services so that the benefits can be experienced by physicians and patients throughout the country, and eventually around the world. I look forward to this challenge.”

The Berlin Citizen
The Bristol Press
New Britain Herald
The Express
Cheshire Citizen
The Chronicle
The Journal Inquirer
Mystic River Press
The North Haven Citizen
The Plainville Citizen
The Southington Citizen
Town Times
Westerly The Sun